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Tumour necrosis factor (TNF) plays an important role in the pathogenesis of immune-mediated
inflammatory diseases (IMIDs). TNF inhibition results in down-regulation of abnormal and progressive
inflammatory processes, resulting in rapid and sustained clinical remission, improved quality of life and
prevention of target organ damage. Adalimumab is the first fully human monoclonal antibody directed
against TNF. In this article, we review the role and cost effectiveness of adalimumab in the treatment
of IMIDs in adults and children. The efficacy and tolerability of adalimumab has been demonstrated in
patients with a wide range of inflammatory conditions, leading to regulatory approval in rheumatoid
arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis, inflammatory bowel diseases (Crohn's disease,
ulcerative colitis, paediatric Crohn's disease, and intestinal Beheet's disease), ankylosing spondylitis
(AS), axial spondyloarthritis (SpA) and juvenile idiopathic arthritis. The major tolerability issues
with adalimumab are class effects, such as injection site reactions and increased risk of infection and
lymphoma. As with all anti-TNF agents, adalimumab is immunogenic, although less than infliximab,
and some patients receiving long-term adalimumab will develop anti-drug antibodies, causing a loss of
response. Comparisons of its clinical utility and cost effectiveness have shown it to be a valid treatment
choice in a wide range of patients. Recent data from Italian economic studies show the cost effectiveness
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of adalimumab to be below the threshold value for health care interventions for most indications. In
addition, analysis of indirect costs shows that adalimumab significantly reduces social costs associated
with RA, PsA, AS, Crohn's disease and psoriasis. The fact that adalimumab has the widest range of
approved indications, many often presenting together in the same patient due to the common pathogenesis,
may further improve the utility of adalimumab. Current clinical evidence shows adalimumab to be a
valuable resource in the management of IMIDs. Further research, designed to identify patients who may
benefit most from this drug, will better highlight the role and cost-effectiveness of this versatile TNF
inhibitor.
Immune-mediated inflammatory disease (lMID)
is the designation given to a range of inflammatory
disorders that share common pathogenic pathways
and a dysregulation of inflammatory cytokines (I).
Indeed, some chronic inflammatory disorders share
overlapping epidemiological, pathogenic, and genetic
features (2, 3), and have been shown to cluster (i.e.
the presence of one disease confers an increased risk
of developing others) in some patients and families.
Examples of these combinations include psoriasis,
psoriatic arthritis (PsA) and Crohn's disease (4-
6), rheumatoid arthritis (RA) and ulcerative colitis
(UC) (7-10), arthropathies and inflammatory bowel
disease (180; Crohn's disease or UC) (II) and
spondyloarthropathies (SpA), PsA and 180 (12).
The cytokine tumour necrosis factor (TNF) plays
an important role in the pathogenesis ofthese chronic
inflammatory conditions and immune-mediated
disorders (13, 14). The inhibition of TNF results in
a down-regulation of the abnormal inflammatory
pathways implicated in the pathogenesis and
progression of IMIDs (15). Biologic response
modifiers targeting TNF - comprising the class
of anti-TNF biotechnological drugs - employed
as monotherapy or in combination with other
immunosuppressive or anti-inflammatory therapies,
have been shown to provide rapid and sustained
clinical remission, improved quality of life (QoL),
prevention of disease progression and, in many
cases, resolution of target organ damage under
chronic conditions (16, 17).
Inference from the latest EULAR guidelines for
treatment of rheumatic diseases with biologic agents
suggests that the ideal anti-TNF agent should be
effective in alleviating symptoms and preventing
radiographic progression of structural damage, and
capable of inducing clinical remission (or even
reversing the existing damage), with rapid onset
of action, persistent effect (no tolerance effect [i.e.
low immunogenicity]) and benign tolerability. It
should also be convenient and easy to administer,
cost effective, and suitable for use in all patient
populations, including the elderly, children and those
with renal and hepatic impairment (16). Although
the ideal anti-TNF drug does not yet exist, among
the available anti-TNF agents, adalimumab, the first
fully human IgG I monoclonal antibody directed
against TNF, has many attributes that make it a valid
clinical choice for long-term treatment of rheumatic
diseases.
Adalimumab binds TNF bivalently, to form
multimeric 'antigen-antibody' complexes, thus
preventing TNF from activating cell surface TNF
receptors, thereby modulating the biological activities
regulated by TNF (14). By comparison, infliximab is
a chimeric mouse-human IgG I monoclonal antibody
and golimumab is a fully human IgG I monoclonal
antibody, and both bind TNF bivalently. Etanercept,
on the other hand, is a TNF receptor-lgG fusion
protein, which consists of the constant Fe fragment
of human IgG I connected by a hinge region to two
extracellular domains of the human TNF receptor
(TNFR) (18), and forms a monovalent bond with
TNF. Certolizumab pegol comprises a single IgG I
Fab' fragment of a humanized monoclonal antibody
bound to two 20 kO polyethylene glycol chains,
which extend the plasma half-life of the drug
(19). Since it is not equipped with an Fe region,
certolizumab interacts with TNF in a monovalent
fashion (20, 21).
Objective and methodology
The aim of this narrative review is to discuss the
place of adalimumab in the treatment of IMIDs in
adults and children, as well as to review economic
data on its potential to provide a cost effective
treatment option compared with other existing
treatments, with particular focus on the economics
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of its multi-indication role in the treatment ofpatients
with more than one IMID. Combined automated
and manual literature searches were performed
in PubMed using the search terms 'adalimumab'
AND 'immune-mediated disease/disorders' AND
['children' OR pediatric/paediatric' OR 'adolescent'
OR 'cross-indication' OR 'disease association' OR
'cost' OR 'economic' or 'pharmacoeconomic'],
From the resulting papers, manual searches were
performed to find relevant papers on adalimumab in
the treatment of immune-mediated disease/disorders.
Current role ofadalimumab
Adalimumab was first approved for treatment of
RA in 2002 and is now indicated for the treatment ofa
wide range ofIMIDs (Table 1) (22). The efficacy and
tolerability of adalimumab has been demonstrated in
several pivotal trials in patients with a wide range of
inflammatory conditions such as RA (23,24), AS (25,
26), axial spondyloarthritis (SpA) (27), PsA (26, 28),
plaque psoriasis (29, 30), Crohn's disease (31, 32),
UC (33, 34) and JIA (12). The clinical data obtained
in these trials have been reviewed in another paper in
this supplement.
The major safety and tolerability issues with
adalimumab include mostly class effects, such as
injection site reactions, increased infection risk
(serious infections, tuberculosis and opportunistic
infections), lymphoma, and other rare events,
including demyelinating disease, autoimmune
phenomena, hematologic toxicities, and congestive
heart failure (35,36). A large cross-indication analysis
of adalimumab safety data, from almost 12 years of
adalimumab exposure in clinical trials, showed that
the most frequently reported serious adverse events
(SAEs) were infections, with the greatest incidence
reported in studies of patients with RA and Crohn's
disease (37). Although the overall malignancy rates
were similar to those in the general population, the
incidence of lymphoma was increased in patients
with RA, and the incidence of non-melanoma skin
cancer was raised in RA, psoriasis and Crohn's
disease (37).
lmmunogenicity
As with all anti-TNF agents, adalimumab is
immunogenic, and over time patients develop anti-
drug antibodies (ADAs) to adalimumab, which
eventually cause tolerance - a reduction in the
pharmacological activity leading to a reduced
efficacy and a need for dose escalation (38, 39).
ADAs, reported particularly with infliximab, are
seen to a lesser extent with adalimumab, occurring
in approximately 20-28% of patients receiving
long-term adalimumab treatment (40). In addition
to reduced efficacy, ADAs are also associated with
safety issues such as anaphylaxis or vasculitis (41).
Combination therapy with non-biologic disease
modifying antirheumatic drugs (DMARDs),
particularly methotrexate (MTX), seems to
reduce the occurrence of ADA formation (40, 42).
Studies assessing immunogenicity, to determine
optimal treatment regimens and concomitant
immunosuppressant therapy to minimize ADA
formation or to investigate the use of neutralizing
immunotherapy to reduce the likelihood of ADA
development, are ongoing (39, 43). In addition to
being dependent on the specific anti-TNF agent
used, immunogenicity and ADA formation appear to
be associated with the mode of administration and
regimen used (40, 44, 45). Generally, subcutaneous
administration is more immunogenic than
intravenous, due to the smaller volumes used, slower
distribution and greater variability of interindividual
drug exposure (45). The likelihood of ADA
formation also appears to be reduced with continuous
maintenance therapy compared with intermittent or
sporadic treatment (44). ADA formation may also
be dependent on the underlying disease, with higher
ADA levels observed in RA, Crohn's disease and
PsA; although this may simply be due to an increased
exposure to biologics or a greater number of clinical
studies in these patient populations.
A range of analytical assays, such as enzyme-
linked immunosorbent assay (ELISA) and
radioimmunoassay (RIA), have been used to detect
and measure ADAs; however, the ADA titre can
vary according to the type of assay used and is
confounded by the presence of circulating anti-TNF
antibodies and rheumatoid factor. Accordingly, the
reported prevalence ofADAs can vary substantially
(44) (Table 2).
IMID cross-indications
Among the available TNF antagonists -
etanercept, infliximab, adalimumab, certolizumab
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Table 1. Adalimumab indications according to labelling (21)
Indication Approval date Details
(country)
Rheumatoid arthritis Dec 2002 (USA) In combination with MTX:
(RA)
Sept 2003 Moderate to severe, active RA in adult patients when the response to
(Europe) DMARDs including MTX has been inadequate
Severe, active and progressive RA in adults not previously treated with
MTX
Can be given as monotherapy in case of intolerance to MTX or when
continued treatment with MTX is inappropriate
Polyarticular juvenile Feb 2008 (USA) In combination with MTX:
idiopathic arthritis
[JIA] Sept 2008 Children and adolescents 4 to 17 years who have had an inadequate
(Europe) response to one or more DMARDs; can be given as monotherapy in case
of intolerance to MTX or when continued treatment with MTX is
inappropriate
Ankylosing spondylitis AS: Jun 2006 Adults with severe active AS who have had an inadequate response to
(AS) and axial (Europe); Jul conventional therapy
spondyloarthritis 2006 (USA)
(AxSp) AxSp without radiographic evidence of AS
AxSp: Jul 2012
(Europe) Severe AxSp without radiographic evidence of AS but with objective
signs of inflammation by elevated CRP and/or MRI, with inadequate
response to, or intolerant to NSAIDs
Psoriatic arthritis Aug 2005 Active and progressive PsA in adults when the response to previous
(PsA) (Europe) DMARDs has been inadequate
Dec 2005 (USA)
Plaque psoriasis Dec 2007 Moderate to severe chronic plaque psoriasis in adult patients who failed
(Europe) to respond to or who have a contraindication to, or are intolerant to other
systemic therapy including cyclosporine, MTX or PUVA
Crohns disease Feb 2007 (USA) Moderately to severely active Crohu's disease, in adult patients who
have not responded despite a full and adequate course of therapy with a
Jun 20007 corticosteroid and/or an immunosuppressant; or who are intolerant to or
(Europe) have medical contraindications for such therapies
Paediatric Crohn's Nov 2012 Moderately to severely active Crohns disease, in children who have not
disease (Europe) responded despite a full and adequate course of therapy with a
corticosteroid and/or an immunosuppressant; or who are intolerant to or
have medical contra indications for such therapies
Ulcerative colitis (UC) April 2012 Moderately to severely active UC in adult patients who have had an
(Europe) inadequate response to conventional therapy including corticosteroids
and 6-mercaptopurine or azathioprine, or who are intolerant to or have
Sept 2012 (USA) medical contraindications for such therapies
Intestinal Behcet's May 2013 (Japan) Intestinal Behcet's disease (Behcet's disease accompanied by intestinal
disease ulcer) in adults refractory to conventional therapies
--
CRp, C-reactive protein; DMARD, disease-modifying antirheumatic drug; MRI, magnetic resonance imaging; MTX, me-
thotrexate; NSAID, non-steroidal anti-inflammatory drug; PUVA, psoralen-ultraviolet A combination therapy.
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Table 2. Frequency of anti-drug antibody (ADA) development reported with anti-tumour necrosis factor (anti-TNF)
therapies (44)
Drug Indication Prevalence reported (% patients)
Adalimumab RA 0.72-87%
AS 31%
PsA 18%
Psoriasis 6-45%
Crohn's disease 0.04--17%
Infliximab RA 10--50%
SpA 15.4--25.5%
AS 18-29%
Crohn's disease 6--61%
PsA 15.4%
Psoriasis 19.5-51.5%
Etanercept RA 0--5.6%
AS 0
PsA 0
Psoriasis 1.1-18.3%
Golimumab RA 0--7%
AS 1.4-4.1%
PsA 4.6-4.9%
Certolizumab RA 5-8.1%
Psoriasis 4--25%
Crohn's disease 3.1-17.7%
AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthropathy.
pegol and golimumab - adalimumab has the widest
employment, having been approved for use in
nine separate IMID indications (RA, PsA, SpA!
AS, Crohn's disease, paediatric Crohn's, UC, JIA,
psoriasis and intestinal Behcet's disease). Within
these indications, IMIDs that have been reported
in the same patient include peripheral arthropathies
+ IBD (46-48), RA + IBD (7-10, 42, 49), RA
+ paediatric UC + Crohn's disease (50), IBD +
psoriasis (4, 6, 49) and PsA + psoriasis + IBD (5).
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Table 3. Clinical studies ofadalimumab in patients with two or more immune-mediated disorders
Reference (study Indications Desi2n N Treatment Endpoints Efficacy outcomes Tolerability
acronym)
Andrisani et al. (42) Seronegative Case study I. 54-yr-old Adalimumab NA Complete remission NR
erosive RA +- female 160/80 rng wk alter I yr
refractory lie 0/2. thcn 40 mg
COY.'
Braun ct al. (52) AS ± psoriasis P.OL 1250 (148 with Adalirnumab 40 ASAS40. ASAS40 46.7% and No correlation of
psoriasis mg cow for 12 BASDAI50 54.7% ofpts skin changes with
(RHAPSODY) wks ±psoriasis AS efficacy
BASDAI5058.6%
and 57.0% otpts
±psoriasis
Kotanierni et al. (55) JlA and uveitis P.OL 94 Adalirnumab Uveitis SUN SUN 2x reduction NR
activity, arthritis (good response) in
activity 28%. moderate
I 7%. no change
17% and worsening
in 13%
l.ofberg et al. (46) Moderate-to-severe P.OL MC 945 (497 with Adalirnurnab Remission rate Wk 20CD Serious infections
CD + cxtraintestinal ElM) 160/80 mg wk HBI <5 remission rate 52%: 5%: well tolerated
(CARE) manifestations 0/2. then 40 mg 51% with ElM free
(ElMS) cow of ElM S&S
Morelli ct al. (56) Psoriatic JIA and Case report 1 Adalirnumab NA Sustained remission NR
uveitis in JIA and uveitis
Rudwaleit et al. (53) AS and peripheral P.OL 1250 (686 with Adalimumab 40 ASAS20. MASES Improvement in NR
arthritis and cnthcsitis and rng cow for 12 MASES ASAS20
(RHAPSODY) cnthesitis 281 with wks in 66.7-71% ofpts
peripheral
arthritis)
Rudwalcit et al. (47) AS and uveitis P.OL 1250 (451 with Adalimurnab 40 Rate of uveitis Wk 20 rate of AU NR
uveitis or h/o mg cow for 20 flares flares reduced hy
(RHAPSODY) uveitis) wks 45-68%
Van der Heijdc ct al. AS (some pts with RCT 315 (95 with Adalirnurnab ASAS20. BASFI. ASA20 58.2% with AEs: 75% (ADA)
(58) uveitis. uveitis. 33 with (n~208) BASDAI, Adalimumab, and vs 59.8% (PBO)
psoriasis) BASMI 20.6% with PBO
PBO (n~I()7) Injection site
reactions: 10.1% vs
2.8%
Yildiz ct al. (57) AS and Behcet's Case study I. 44-yr-old male Adalimumab 40 NA Remission of AS NR
mgeow and BD
Zannin ct al. (54) JIA and AU Observational 108 (91 with 12- Adalimumab Change in uveitis AU remission No SAEs
registry 1110 follow-up) (n~43) course and in 55.3%
number of ocular (Adalimumab Minor AE in 8.8%
IFX (n~48) complications 67.4%. IFX 42.8%: (II Aes, 9 with IFX
p~0.025) and 2 with
Adalimurnab)
Reduction in ocular
complications
AS. ankylosing spondylitis; ASAS20. ?20% improvement in Assessment ofAnkylosing Spondylitis response criteria; AU,
anterior uveitis; BASFI. Bath Ankylosing Spondylitis Functional Index; BASDAI, Bath Ankylosing Spondylitis Disease
Activity Index: BASMI. Bath Ankylosing Spondylitis Metrology Index; BD, Behcet s disease; CD. Crohn s Disease; DB,
double-blind; ElM, extraintestinal manifestations; eow, every other week; HBI. Harvey-Bradshaw Index; h/o, history of
IFX, injliximab; MASES, Maastricht ankylosing spondylitis enthesitis score; MC, multicentre; NA, not applicable; NR,
not reported; OL, open-label; P, prospective: PBO, placebo; PC, placebo-controlled; pts, patients; R, randomised; RA,
rheumatoid arthritis; RCT, randomised controlled trial; S&S, signs and symptoms; SUN, Standardized Uveitis Nomen-
clature; UC, ulcerative colitis; JIA, juvenile idiopathic arthritis
Int. J. Immunopathol. Pharmaeol.
Table 4. Adalimumab ongoing/unpublished trials in off-label indications [Source: ClinicaITrials.gov]
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CliniealTrial.gov Indications Design Status Phase Treatment Primary endpoint Estimated N Estimated
number (Study study
acronym) completion
date
NCTO I 138657 Active uveitis R. DB. Pc. Recruiting III Adalimumab Time to treatment failure 250 Nov 2014
VISUAL I MC Prednisone
PBO
NCTOl124838 Inactive uveitis R. DB. Pc. Recruiting III Adalimumab Time to treatment failure 250 Oct 2014
VISUAL II Me
Prednisone
PBO
NCT01148225 Non-infectious MC,Ol Enrolling by III Adalimumab AEs. Lab parameters and 400 Mar 2016
VISUAL III uveitis invitation only vital signs
Prednisone
PBO
NCTOO274352 Cutaneous R. CO. Pc. Completed II Adalimumab Week-12 responders (pts 16 Feb 2012 (not
sarcoidosis DB achieved at least a yet published)
moderate improvement on
PGAj
NCTO 1166282 Enthesitis-related R. DB. PC Active. not III Adalimumab % change in number of 45 Dec 2015
JIA recruiting active joints; AEs
PBO
NCT01219257 Spondyloarthritis Prospective, Unknown NR Anti-TNF Sensitivity to change of US 100 Nov 2013
UlSPABIT observational pathology in joints and
(extension of en theses
NORDMARD study)
-NCT01251614 Juvenile chronic R. DB. PG. Active, not III Adalimumab PASI75. PGA. AEs III Jan2015
plaque psoriasis MC recruiting low dose and
standard dose
vsMTX
NCT01497717 Behcer's disease Ol Recruiting III Adalimumab Reduction in DAS28 15 Sept 2016
and arthritis
NCTOl960790 Intestinal Observational Recruiting NR Adalimumab AEs 250 May 2017
Bch<;et's disease
AE, adverse event; CO, crossover; DAS28, Disease activity score in 28 joints; JIA, juvenile idiopathic arthritis; MC,
multicentre; MTX, methotrexate; NR, not reported; OL. open-label; PASI 75, the proportion of subjects achieving
a Psoriasis Area and Severity Index 75 response; PBO, placebo; PC. placebo-controlled; PG, parallel-group; PGA,
physicians 'global assessment; R, randomized; US, ultrasound.
Analyses of data from observational studies have
also revealed the incidence of some co-occurring
IMIDs. The prospective population-based IBSEN
study, for example, showed that peripheral arthritis
occurs in about 12% of patients with IBD in the first
year of IBD diagnosis (51). Association of RA with
IBD in the same patient is less common and has been
described in a few case studies (9, 42), although a
large cross-sectional study showed that IBD patients
were more likely to have other inflammatory
diseases, including psoriasis and RA (49). In another
large study in 174,476 women with psoriasis and
PsA, psoriasis was associated with a significantly
increased risk of subsequent Crohn's disease, but not
UC, with an increased risk ofCrohn's disease among
women with psoriasis and PsA (6).
Adalimumab clinical data in patients with two or
moreIMIDs
As a result of several case reports suggesting the
efficacy of adalimumab in co-occurring IMIDs (42),
clinical trials, such as the RHAPSODY and CARE
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studies, have investigated the efficacy and tolerability
of adalimumab in co-occurring IMIDs (46, 47). The
preliminary evidence from adalimumab clinical and
case studies in patients with two or more immune-
mediated disorders are summarised in Table 3.
Most data are from the AS RHAPSODY study - a
l2-week open-label study of adalimumab in patients
with AS. In one analysis, evaluating patients with
AS and psoriasis (12% of the cohort), adalimumab
treatment resulted in significant improvements in AS
clinical parameters (axial disease, peripheral arthritis
and enthesitis), but skin changes did not correlate
with changes in AS symptoms (52). In addition,
among patients with AS, 686 with enthesitis and
281 with peripheral arthritis, adalimumab not only
reduced symptoms of active AS but also improved
enthesitis and peripheral arthritis (53). In another
RHAPSODY analysis in 274 patients with AS and a
history ofanterior uveitis (AU), adalimumab resulted
in a 58% reduction of uveitis flares; this included a
68% reduction in patients with a recent history of
AU, 50% reduction in patients with symptomatic
AU at baseline and 45% reduction in patients with
chronic uveitis (47).
Several papers have reported adalimumab
efficacy in patients with JIA and uveitis. The
National Italian Registry has evaluated the safety
and efficacy of adalimumab (n=43) and infliximab
(n=48) in patients with JIA-AU refractory to standard
immunosuppressive treatment and treated ~ I year,
showing that AU remission was achieved in 55.3%
of patients (67.4% vs 42.8% with adalimumab and
infliximab, respectively; p = 0.025) (54).
In a long-term study ofthe efficacy ofadalimumab
in 94 patients with JIA and uveitis, adalimumab was
effective in the control of JIA and uveitis symptoms,
and allowed a reduction in corticosteroid use (55).
Adalimumab was also shown to be effective in a
patient with psoriatic JIA and uveitis failing NSAID,
MTX and etanercept therapy, resulting in remission
of both conditions (56) and, in another case report,
adalimumab was effective in a patient with AS and
Behcet's disease (57).
In a l2-week randomised controlled trial of
208 patients with AS treated with adalimumab,
33% had uveitis and 8% had psoriasis at baseline,
although the status of the combined conditions
at endpoint was not reported (58). An ASAS20
(~20% improvement in Assessment in Ankylosing
Spondylitis response criteria) response was achieved
in 58.2% of adalimumab-treated patients versus
20.6% with placebo (p<O.OO I). Other AS parameters
(the Bath Ankylosing Spondylitis Functional Index
[BASFI], the Bath Ankylosing Spondylitis Disease
Activity Index [BASDAI], and the Bath Ankylosing
Spondylitis Metrology Index [BASMI], etc.) were
also significantly improved with adalimumab versus
placebo (58).
Results from the phase IIIb open-label CARE
study in 945 patients with moderate-to-severe
Crohn's disease and extraintestinal manifestations
(ElMs), showed that adalimumab achieved clinical
remission and resolution of ElMs in the majority of
patients overall and achieved substantial rates even
in patients previously failing infliximab (46).
Finally, a case report of successful adalimumab
treatment in a patient with refractory UC and
seronegative erosive RA, showed that adalimumab
resulted in a sustained remission (42). The use of
adalimumab in patients with two or more immune-
mediated diseases has also shown efficacy in other
off-label conditions, but most data are anecdotal
and are not the focus of this review. However, this
anecdotal evidence has led to a very active Phase III
clinical development programme for adalimumab
(Table 4).
Adalimumab in paediatric diseases
There is an urgent need for effective and better
tolerated treatments in paediatric patients, as
IMIDs are often more severe in younger patients
and many are not adequately controlled with the
available DMARDs. Furthermore, several biologic
agents have tolerability issues that make their use
problematic in children. The benign tolerability
profile of adalimumab has led to its early approved
use in children and adolescents (59-61). Indeed
adalimumab is currently approved for use in
JIA (formerly designated as juvenile rheumatoid
arthritis [JRA]) and paediatric Crohn's disease (59-
61). However, adalimumab has not been studied
in children aged <2 years old, and limited data are
available in children weighing less than 15 kg (21).
Juvenile idiopathic arthritis
JIA is a chronic inflammatory disorder defined
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as arthritis that persists for ::.::6 weeks in children
and adolescents aged < 16 years without any other
identifiable cause (62). The prevalence of significant
paediatric arthritis and otherrheumatologic conditions
has been estimated in the US at approximately
294,000, based on ICD-9-CM estimates (63). As
with other IMIDs, treatment for JIA has evolved from
symptom-based treatment, to the use of DMARDs
such as MTX, corticosteroids, and the biologic drugs
etanercept and adalimumab. Adalimumab has shown
excellent efficacy and tolerability in patients with
JIA. For example in one study in six patients failing
MTX, infliximab and etanercept therapy, adalimumab
24 mg/mvweek plus MTX resulted in a sustained
improvement or remission in three children and was
well tolerated (64). In a 16-week, single-arm, open-
label study of adalimumab in 25 Japanese patients
with JIA, the American College of Rheumatology
(ACR) Pedi30 (::'::30% improvement in ACR pediatric
JIA response criteria) response rates at week 16 were
90% and 100% with and without MTX, and the
clinical response was maintained up to week 60 in
most patients. Of the 25 patients, six patients (all
with concomitant MTX therapy) experienced nine
serious AEs (65).
Paediatric Crohn sdisease
The majority of children with IBD have Crohn's
disease, although paediatric UC and indeterminate
colitis are also observed. Crohn's disease is a disorder
of the young population, with about a quarter of
cases presenting in children and young people
(66). Complications, such as impaired growth,
delayed puberty and low bone density, are caused by
malnutrition in children with active Crohn's disease
(67). As with adult Crohn's disease, the prevalence
has increased in recent years in developed countries,
with one US study estimating the prevalence at
almost 5 cases per 100,000, which is twice that of
paediatric UC (68). The burden ofdisease is probably
increasing due in part to a trend towards an earlier
age of onset (69) and partly to improved diagnosis
(70).
Conventional treatments, such as corticosteroids,
immunosuppressants and non-biological DMARDs,
are currently employed, as most biological
therapies are not approved for use in children (71).
Adalimumab has been shown to be effective and well
tolerated in children with Crohn's disease (59, 72-
75) and is one ofonly two anti-TNF agents approved
for use in paediatric Crohn's disease (the other being
infliximab). The clinical efficacy and tolerability
of adalimumab was investigated in the 12-month
IMAgiNE I study - a pivotal trial in 192 children
with paediatric Crohn's disease (59). After 2 weeks
of open-label induction therapy with subcutaneous
adalimumab at weeks 0 and 2 (160/80 mg or 80/40
mg for body weight ::.::40 kg or <40 kg, respectively),
children were assigned to high (40 or 20 mg) or low
dose (20 or 10 mg) adalimumab every other week
(eow) for 48 weeks. After 6 months of adalimumab
therapy, 33.5% ofpatients achieved clinical remission
and the treatment was well tolerated, with a safety
profile similar to that recorded in adults with Crohn's
disease (59). In a 12-month study investigating the
effect of adalimumab on growth in 36 children with
Crohn's disease, remission was achieved in 78% and
catch-up growth, occurring in 42% of children with
adalimumab, was more likely in those who achieved
remission (76).
Pharmacoeconomic considerations
A Health Technology Assessment (HTA) in
RA patients failing one anti-TNF inhibitor showed
that, compared with DMARDs, the incremental
cost-effectiveness ratios (ICERs) were lowest for
adalimumab, followed by etanercept and then
infliximab (77). A review ofeight pharmacoeconomic
studies evaluating the cost ofadalimumab, etanercept,
and infliximab in the management of RA showed
that overall, biologic therapies cost considerably
more than traditional DMARDs, but produce more
quality-adjusted life-years (QALYs) (78).
Pharmacoeconomic studies with a societal
perspective, that take indirect costs and social
outcomes such as work productivity into account,
indicate that the benefits provided by adalimumab in
terms of improved work productivity, for example,
could lend to considerable socio-economic benefits
compared with conventional treatment in Crohn's
disease (79, 80).
More recently, an Italian group developed two
economic evaluation models (81, 82) estimating,
in the Social Cost Study (82), the global social cost
in terms of lost productivity due to RA, PsA, AS,
Crohn's disease and psoriasis, and, in the COVET
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Study (81), estimating the overall economic value of
a single multi-indication drug (adalimumab) versus a
multi-drug prescription.
Assessment of indirect costs is extremely
important when managing chronic diseases. Patients'
lost productivity is often overlooked by decision-
makers, although it is fundamental for estimation of
the true economic impact of disease. Therefore, the
Social Cost Study (82) estimated the social savings
obtained with adalimumab compared with standard
therapies for treatment of RA, PsA, AS, Crohn's
disease and psoriasis, in the Italian population.
Five different economic models were developed by
external consultants to estimate the cost utility of
adalimumab versus standard care for each of the five
diseases. Both Italian National Health System (direct
costs) and social (direct costs + loss of productivity)
perspectives were adopted. For each indication, the
models calculated the annual loss ofproductivity per
patient with standard therapy and with adalimumab.
A sensitivity analysis, based on the variability
of model parameters, was performed in order to
assess the robustness of the results. In the base-case
scenario, the average annual social cost (weighted
for prevalence of eligible patients for biologic
treatment of each indication) per patient amounted
to € 1,421 if treated with standard care, compared
with €744 with adalimumab. Adalimumab treatment
provided an 8.1% (€40 million) reduction in the total
social cost, and an annual saving in social costs of
7.0-11.0%, assuming 17% of market penetration for
patients eligible for biologic use. The results showed
that adalimumab has a significant impact in reducing
social costs for all the indications considered.
These aspects, often neglected in decision makers'
assessments, should be included in the overall
evaluation of benefits of innovative technologies
such as biologic drugs.
The value of a drug can also be expressed as
the cost needed to increase a unit of health (e.g.
QALV); however, summarizing the economic
value of a molecule with multiple indications is a
complex process. The COVET study provided a
comprehensive economic evaluation of adalimumab
across all five indications approved at the time of
the analysis (81). An algorithm was developed to
estimate the total economic value of adalimumab.
This value was calculated as the sum of ICERs
for treating RA, PsA, AS, Crohn's disease, and
psoriasis from an Italian National Health System
(NHS) perspective. Estimates of the cost per QALY
gained for adalimumab versus standard therapy
were derived from previously developed economic
models. The sum was weighted according to the
prevalence of each of the indications considered.
Using a systematic literature review, the cost per
QALY gained by using other anti-TNF drugs was
extrapolated. Subsequently, a Boston matrix was
developed to establish the economic cumulative
value, i.e. the relationship between demand (i.e.,
prevalence of patients treatable with biologics for
each disease) and supply (e.g., willingness to pay
[WTP] threshold of the healthcare authorities),
relative to ICER. Using a societal perspective
and the highest value of each model, a one-way
sensitivity analysis was performed to test the
robustness of the results. The total economic value
of adalimumab in Italy amounted to €35,854 per
QALY. The sensitivity analysis showed that the cost
per QALY gained ranged from €27,758 to €40,799.
Analysis ofthe Boston matrix indicated that, with the
exception of psoriasis, the cost per QALY gained by
using adalimumab instead of standard therapy was
below the common WTP threshold. For psoriasis,
the cost per QALY for adalimumab was over the
WTP threshold, but this is a situation common to
all biologic drugs, and adalimumab has the best cost
effectiveness ratio. Overall, in comparison with other
biologics, the total economic value of adalimumab
was positive and sustainable. This should encourage
decision makers to facilitate patient access to this
cost-effective treatment. The findings may also
promote research to develop innovative molecules
that are even more cost effective.
Impact on treatment guidelines
Current European and Italian guidelines for
management of RA, published by the European
League Against Rheumatism (EULAR) (16, 83-86),
recommend that biologics should be used as second-
line therapy only after MTX (or other DMARD)
failure. Biological agents should be administered
in combination with MTX, in patients failing to
respond to non-biologic DMARD within 6 months
and when poor prognostic factors are present (84).
ACR guidelines for RA treatment, on the other hand
Int. J. Immunopathol. Pharmacol. 43 (S)
(87), recommend the use of an anti-TNF, with or
without MTX, in patients with early RA (less than 6
months' duration) with high disease activity and poor
prognostic features.
Given the benefits demonstrated in early disease
(mainly in RA but also in other 1MIDs), there is a
need for better prognostic indicators and patient risk
stratification algorithms to allow identification and
selection of those most likely to benefit from first-
line adalimumab therapy - either as monotherapy
or in combination with MTX. Long-term outcome
studies are also needed to provide data for prognostic,
predictive and pharmacoeconomic analyses to inform
future treatment guidelines.
Although the drug costs of biological agents
is considerably higher than that of non-biological
DMARDs, many of these extra costs are offset by
savings in terms of reduced hospitalisation, reduced
number of outpatient visits, etc. In this respect,
further research and data are required to demonstrate
the overall cost-effectiveness ofanti-TNFs from both
a healthcare and socioeconomic perspective, the
latter taking into account the substantial indirect cost
savings resulting from improved work productivity,
reduced absenteeism, reduced care costs and
assistance with daily living, and improved patient
quality of life (88).
The fact that adalimumab has the widest range of
approved indications, including many disorders often
presenting together in the same patient, may further
improve the cost effectiveness of adalimumab,
since the use of a multi-indication drug to treat
two or more indications in the same patient would
decrease considerably the drug burden. This would
make adalimumab very valuable for treatment of co-
occurring IMIDs.
CONCLUSIONS
Current data demonstrate that adalimumab is a
valuable resource in the management of IMIDs. It
has proven efficacy and tolerability in a wide range
of indications, many of which can be found in the
same patient due to their common pathogenesis,
and it has been shown also to be suitable in the
management of paediatric IMIDs. Comparisons of
clinical utility and cost-effectiveness support the
view that adalimumab is a valid treatment choice in
a wide range of patients. Recent Italian economic
studies provide a first indication ofthe total economic
value of adalimumab, showing it to be below the
threshold value for health care interventions for all
the main indications. In addition, analysis of indirect
costs shows that adalimumab significantly reduces
societal costs associated with RA, PsA, AS, Crohn's
disease and psoriasis.
As a multi-indication drug, adalimumab is
expected to have greater pharmacoeconomic benefits
in comparison with biologics with a more restricted
range of indications, when used to treat two or more
indications in the same patient. However, taking all
costs into account, the current economic differences
appear to be marginal in clinical practice; this may
be due to difference in recorded indications. For
example, it is unavoidable that the more recently
marketed drugs have fewer recorded indications due
to their 'youth' in the market. Comparison among
indications makes sense only between adalimumab
and etanercept, where the lack of effectiveness of
etanercept in granulomatous diseases (e.g. Crohn's
disease) is certain. However, despite rational
aetiopathogenic considerations, information
comparing one drug with another in patients with
specific disease associations is limited.
Additional research is required to better identify
patients who may benefit most from treatments with
adalimumab, as well as to expand the range ofuse of
this versatile TNF inhibitor.
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